CVE:ICOiCo Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding iCo Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$0.05 +0.01 (+25.00 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's RangeC$0.04Now: C$0.05▼C$0.0550-Day RangeC$0.04MA: C$0.05▼C$0.0652-Week RangeC$0.02Now: C$0.05▼C$0.15Volume12,600 shsAverage Volume530,487 shsMarket CapitalizationC$7.69 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for iCo Therapeutics. Previous Next 2.4 Community Rank Outperform VotesiCo Therapeutics has received 50 “outperform” votes. (Add your “outperform” vote.)Underperform VotesiCo Therapeutics has received 56 “underperform” votes. (Add your “underperform” vote.)Community SentimentiCo Therapeutics has received 52.83% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about iCo Therapeutics and other stocks. Vote “Outperform” if you believe ICO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ICO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldiCo Therapeutics does not currently pay a dividend.Dividend GrowthiCo Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, iCo Therapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of iCo Therapeutics is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iCo Therapeutics is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiCo Therapeutics has a P/B Ratio of 12.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:ICO Previous Symbol CUSIPN/A CIKN/A Webwww.icotherapeutics.com Phone+1-604-6029414Debt Debt-to-Equity RatioN/A Current Ratio1.81 Quick Ratio1.74Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.01 per share Price / Cash Flow8.33 Book ValueC$0.00 per share Price / Book12.50Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares153,748,000Market CapC$7.69 million Next Earnings Date6/4/2020 (Estimated) OptionableNot Optionable TSXV:ICO Rates by TradingView Receive ICO News and Ratings via Email Sign-up to receive the latest news and ratings for ICO and its competitors with MarketBeat's FREE daily newsletter. iCo Therapeutics (CVE:ICO) Frequently Asked Questions How has iCo Therapeutics' stock been impacted by COVID-19 (Coronavirus)? iCo Therapeutics' stock was trading at C$0.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ICO stock has increased by 11.1% and is now trading at C$0.05. View which stocks have been most impacted by Coronavirus. When is iCo Therapeutics' next earnings date? iCo Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, June 4th 2020. View our earnings forecast for iCo Therapeutics. Has iCo Therapeutics been receiving favorable news coverage? News headlines about ICO stock have been trending very negative on Sunday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. iCo Therapeutics earned a coverage optimism score of -3.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutiCo Therapeutics. Who are some of iCo Therapeutics' key competitors? Some companies that are related to iCo Therapeutics include ImmuPharma (IMM), Kazia Therapeutics (KZA), NovaBay Pharmaceuticals (NBY), Biocardia (BCDA), Nuformix (NFX), Noxopharm (NOX), Prana Biotechnology (PBT), Scancell (SCLP), Hemogenyx Pharmaceuticals (HEMO), Armata Pharmaceuticals (ARMP), Bio-Gene Technology (BGT), Fusion Antibodies (FAB), NovaBay Pharmaceuticals (NBY), Oragenics (OGEN) and Bionomics (BNO). View all competitors. What other stocks do shareholders of iCo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other iCo Therapeutics investors own include iCo Therapeutics (ICOTF), Theratechnologies (TH), Regulus Therapeutics (RGLS), Nemaska Lithium (NMX), Freeport-McMoRan (FCX), Eldorado Gold (EGO), Dextera Surgical (DXTR), Aurora Cannabis (ACBFF) and Aurora Cannabis (ACB). Who are iCo Therapeutics' key executives? iCo Therapeutics' management team includes the following people: Mr. Andrew J. Rae M.B.A., BSc, MBA, Co-Founder, CEO, Pres & Director (Age 52)Mr. Michael Liggett CPA, CA, Bsc. Pharm., CFO, Corp. Sec. & Director (Age 59)Dr. Peter Hnik M.D., MHSc, Chief Medical Officer (Age 63) What is iCo Therapeutics' stock symbol? iCo Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ICO." How do I buy shares of iCo Therapeutics? Shares of ICO and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is iCo Therapeutics' stock price today? One share of ICO stock can currently be purchased for approximately C$0.05. How big of a company is iCo Therapeutics? iCo Therapeutics has a market capitalization of C$7.69 million. What is iCo Therapeutics' official website? The official website for iCo Therapeutics is www.icotherapeutics.com. How can I contact iCo Therapeutics? iCo Therapeutics' mailing address is 760-777 Hornby St, VANCOUVER, BC V6Z 1S4, Canada. The company can be reached via phone at +1-604-6029414. This page was last updated on 5/31/2020 by MarketBeat.com Staff
